目前肝癌主要治疗方法为手术切除、局部或全身化疗等,尽管患者的长期生存率有所提高,但术后5年复发率仍在43%～61%[1],为预防术后复发、治疗不能手术切除或不能耐受化疗的病人,人们一直在寻求一种更有效的治疗方法。随着现代分子生物学、免疫生物学、肿瘤免疫治疗学的发展,人们 At present, the main treatment for liver cancer is surgical resection, local or systemic chemotherapy. Although the long-term survival rate of patients is increased, the recurrence rate is still 43% to 61% after 5 years[1]. It is to prevent postoperative recurrence and treatment. Patients who cannot be surgically removed or who cannot tolerate chemotherapy have always sought a more effective treatment. With the development of modern molecular biology, immunobiology, and tumor immunotherapy, people